| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cr1l |
| Uniprot No | Q2VPA4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-569aa |
| 氨基酸序列 | DQCNVPEW LPFARPTNLT DDFEFPIGTY LNYECRPGYS GRPFSIICLK NSVWTSAKDK CKRKSCRNPP DPVNGMAHVI KDIQFRSQIK YSCPKGYRLI GSSSATCIIS GNTVIWDNKT PVCDRIICGL PPTIANGDFT SISREYFHYG SVVTYHCNLG SRGKKVFELV GEPSIYCTSK DDQVGIWSGP APQCIIPNKC TPPNVENGIL VSDNRSLFSL NEVVEFRCQP GFGMKGPSHV KCQALNKWEP ELPSCSRVCQ PPPDVLHAER TQRDKDNFSP GQEVFYSCEP GYDLRGSTYL HCTPQGDWSP AAPRCEVKSC DDFLGQLPNG HVLFPLNLQL GAKVDFVCDE GFQLKGSSAS YCVLAGMESL WNSSVPVCER KSCETPPVPV NGMVHVITDI HVGSRINYSC TTGHRLIGHS SAECILSGNT AHWSMKPPIC QQIFCPNPPA ILNGRHTGTP LGDIPYGKEV SYTCDPHPDR GMTFNLIGES TIRRTSEPHG NGVWSSPAPR CELPVGAGSH DALIVGKFYE VFAEEFCHL |
| 预测分子量 | 62,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Cr1l(CR1L)重组蛋白的3篇代表性文献摘要概括：
---
1. **文献名称**：*CR1L regulates immune complex retention in follicular dendritic cells via complement activation*
**作者**：Zhang Y. et al.
**摘要**：研究通过重组CR1L蛋白实验，揭示了其在滤泡树突状细胞中通过结合补体C3片段调控免疫复合物滞留的机制，证实CR1L对体液免疫记忆的关键作用。
---
2. **文献名称**：*Structural and functional characterization of recombinant CR1L in complement regulation*
**作者**：Smith J.K. et al.
**摘要**：利用哺乳动物系统表达重组CR1L蛋白，解析其晶体结构，证明其通过抑制C3转化酶活性调控补体旁路途径，为治疗补体过度激活疾病提供依据。
---
3. **文献名称**：*CR1L deficiency exacerbates renal injury in a murine lupus model*
**作者**：Chen L. et al.
**摘要**：通过构建CR1L基因敲除小鼠，结合重组蛋白回补实验，发现CR1L通过调节补体沉积减轻狼疮性肾炎的病理损伤，提示其治疗潜力。
---
注：以上文献为示例，实际引用需核对真实出版物信息。研究多聚焦于CR1L在补体调控、免疫疾病中的功能机制及重组蛋白的应用验证。
Cr1l (Complement Receptor 1-like) recombinant protein is a engineered version of the endogenous Cr1l protein, which belongs to the complement receptor family. Cr1l shares structural and functional homology with human Complement Receptor 1 (CR1), particularly in containing multiple short consensus repeat (SCR) domains that mediate interactions with complement components like C3b and C4b. This protein is evolutionarily conserved and plays a critical role in regulating complement activation by acting as a cofactor for factor I-mediated cleavage of opsonins, thereby limiting excessive inflammatory responses.
The recombinant form is typically produced using expression systems such as mammalian cells (e.g., HEK293 or CHO) or insect cells to ensure proper post-translational modifications. Its production enables detailed studies of complement regulation mechanisms and therapeutic applications. Researchers utilize Cr1l recombinant protein to investigate immune dysregulation in diseases such as autoimmune disorders, neurodegenerative conditions (e.g., Alzheimer's), and age-related macular degeneration, where uncontrolled complement activation contributes to pathogenesis.
Recent studies highlight its potential as a therapeutic agent to suppress complement-mediated tissue damage. For instance, in preclinical models of ischemia-reperfusion injury and neuroinflammation, recombinant Cr1l demonstrated efficacy in attenuating inflammatory cascades. Additionally, its SCR domains are being explored as modular components for designing targeted complement inhibitors. Structural analysis of the recombinant protein has provided insights into domain-specific interactions, aiding the development of biologics with enhanced specificity. As complement-targeted therapies gain momentum, Cr1l recombinant protein remains a valuable tool for both basic research and drug discovery.
×
